September 15, 2020
“The U.S. has a vibrant and thriving biopharma sector” – says American Enterprise Institute scholar and Milton Friedman chair James C. Capretta – “in large part because the payments system for these products is more favorable to the industry than it is elsewhere.”
Prescription Drug Q&A: The U.S. market-based system makes it a world leader in discovering new medicines
Americans get what they pay for when it comes to prescription drugs. We pay higher prices for drugs but gain access to nearly twice as many new medicines as citizens in foreign countries that use the law or government programs to set drug prices.
With another U.S. Supreme Court term beginning, there are more opportunities for guidance and protection of religious freedom. To understand these opportunities, we asked Howard Slugh some questions about religious freedom cases in the upcoming court term.